GeneOne Life Science, Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From GeneOne Life Science, Inc.
BioNTech and MediLink’s HER3 ADC Back In The Game After Safety Concerns
The partners still believe their HER3-targeting ADC can rival Merck & Co and Daiichi Sankyo’s frontrunner, even at a new lower dose range.
Eisai Regains Full Control Of ADC Program After Bristol R&D Reprioritization
The Japanese pharma said it plans to accelerate development of the antibody-drug conjugate farletuzumab ecteribulin for solid tumors and will develop it independently.
China Sets Clinical Trial Record But Starting Studies Can Be Challenging
Antibody-drug conjugates, GLP-1 receptor agonists and cell/gene therapies propelled a big increase in clinical trial registrations in China last year, but why do sponsors sometimes remain reluctant to actually start studies?
BMS Will Cut $1.5bn And 2,200 Jobs To Reinvest In Needed Growth
Revlimid and Eliquis beat expectations in the first quarter, but the products have dwindling exclusivity, making new drugs the main focus for Bristol. So the company will reinvest cost savings in R&D.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
- Distributors
-
Services
- Consulting Services
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- ADMET
- Other Names / Subsidiaries
-
- VGXI, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice